Sugi Predict

Sugi Predict / Compounds / SCHEMBL348156

SCHEMBL348156

SCHEMBL348156

COc1cc(C(N)=O)c([N+](=O)[O-])cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.57
▸ POLB P06746 3/20 0.57
▸ HTT P42858 1/20 0.57
▸ CYP3A4 P08684 3/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ MAPT P10636 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ PRKDC P78527 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ CASP3 P42574 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51
▸ SENP6 Q9GZR1 1/20 0.51
▸ PKM P14618 1/20 0.50
▸ CTDSP1 Q9GZU7 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5502239 0.89 POLB (0.47) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL2840392 0.89 POLB (0.47) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL6815706 0.88 POLB (0.49) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL873870 0.87 POLB (0.53) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL2313877 0.87 LMNA (0.46) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL2605630 0.86 LMNA (0.73) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL375897 0.84 PKM (0.59) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL4108486 0.84 L3MBTL1 (0.59) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL31549975 0.84 PKM (0.59) LMNAPOLBHTTCYP3A4L3MBTL1
SCHEMBL30716507 0.84 L3MBTL1 (0.59) LMNAPOLBHTTCYP3A4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9441199-B2 Cells exhibiting neuronal progenitor cell characteristics and methods of making them SANBIO, INC. (US) 2016-09-13 — — US claimed
US-20150267169-A1 CELLS EXHIBITING NEURONAL PROGENITOR CELL CHARACTERISTICS AND METHODS OF MAKING THEM SANBIO, INC. (US) 2015-09-24 — — US claimed
US-20140065133-A1 JAK/STAT INHIBITORS AND MAPK/ERK INHIBITORS FOR RSV INFECTION UNIVERSITY OF SOUTH FLORIDA (US) 2014-03-06 — — US claimed
US-8592368-B2 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection UNIVERSITY OF SOUTH FLORIDA (US) 2013-11-26 — — US claimed
EP-1875900-A2 JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis GENZYME CORPORATION (US) 2008-01-09 — — EP claimed
US-20050159385-A1 JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection SOUTH FLORIDA, UNIVERSITY OF 2005-07-21 — — US claimed
CN-115260164-B Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs 杭州星鳌生物科技有限公司 2024-03-26 — — CN disclosed
CN-117603219-A P-glycoprotein inhibitor and preparation method and application thereof 浙江大学 2024-02-27 — — CN disclosed
WO-2023250140-A1 STAT3 INHIBITOR TO TREAT SUBARACHNOID HEMORRHAGE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-12-28 — — WO disclosed
WO-2022233253-A1 METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS 杭州星鳌生物科技有限公司 2022-11-10 — — WO disclosed
CN-115260164-A Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs 杭州星鳌生物科技有限公司 2022-11-01 — — CN disclosed
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2021-11-25 — — US disclosed
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
WO-2000000202-A1 METHOD FOR INHIBITING C-JUN EXPRESSION USING JAK-3 INHIBITORS PARKER HUGHES INSTITUTE (US) 2000-01-06 — — WO disclosed
WO-1999061428-A1 QUINAZOLINES FOR TREATING BRAIN TUMOR PARKER HUGHES INSTITUTE (US) 1999-12-02 — — WO disclosed
CN-1169986-A 2.9-diamino-and 2-amino-8-carbamoyl-4-hydroxy-aldanoic acid amide derivatives CIBA GEIGY AG (CH) 1998-01-14 — — CN disclosed
CN-1150948-A Preparation method of 6,7-dimethoxy-2,4-(1H,3H)-quinazoline diketon SHENYANG MEDICINE UNIV (CN) 1997-06-04 — — CN disclosed
EP-0251143-B1 2-Oxo-1-[[(Substituted Sulfonyl)Amino]-Carbonyl]Azetidines Bristol-Myers Squibb GmbH (DE) 1992-08-26 — — EP disclosed
US-4801705-A 2-oxo-1-(((substituted sulfonyl)amino)-carbonyl)azetidines E. R. SQUIBB & SONS, INC. (US) 1989-01-31 — — US disclosed
EP-0251143-A1 2-Oxo-1-[[(Substituted Sulfonyl)Amino]-Carbonyl]Azetidines Bristol-Myers Squibb GmbH (DE) 1988-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210361656-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 LMNA 489/4885POLB 2324/4885HTT 1248/4885
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 LMNA 3392/4885POLB 3468/4885HTT 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.